TriSalus Life Sciences (TLSI) Long-Term Investments (2020 - 2023)

TriSalus Life Sciences' Long-Term Investments history runs 4 years deep, the most recent figure standing at $12.1 million for Q2 2023.

• On a quarterly basis, Long-Term Investments fell 95.18% year-over-year to $12.1 million in Q2 2023; TTM through Jun 2023 was $12.1 million, a 95.18% decrease from a year earlier, with the FY2022 full-year figure at $19.8 million, down 92.07% from the prior year.
• Long-Term Investments eased to $12.1 million in Q2 2023 per TLSI's latest filing, from $20.2 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $251.0 million in Q3 2022 and bottomed at $12.1 million in Q2 2023.
• The 4-year median for Long-Term Investments is $250.0 million (2021), against an average of $186.7 million.
• Across the five-year window, Long-Term Investments rose 0.38% in 2022 and slumped 95.18% in 2023, its largest moves.
• Year by year, Long-Term Investments stood at $250.0 million in 2020, then advanced by 0.0% to $250.0 million in 2021, then slumped by 92.07% to $19.8 million in 2022, then sank by 39.09% to $12.1 million in 2023.
• Per Business Quant, the three latest TLSI Long-Term Investments figures stand at $12.1 million (Q2 2023), $20.2 million (Q1 2023), and $19.8 million (Q4 2022).